Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

ConditionRenal Cell Carcinoma (Kidney Cancer)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

About this trial

This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026;

Aged > 18 years old;

At least one abdominal CT scan before treatment;

Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma.

Disqualifiers

Poor image quality;

Incomplete clinical data or loss of follow-up;

Presence of another primary malignancy other than renal cell carcinoma;

Unclear pathological diagnosis.

Trial population

Patients were treated for renal cell carcinoma

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Progression-free survival

Time frame

1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Lead sponsor

Source ClinicalTrials.gov

Apply now